<DOC>
	<DOC>NCT00971802</DOC>
	<brief_summary>To evaluate the safety and tolerability of PF-03882845 in Healthy Volunteers. To evaluate the pharmacokinetics of PF-03882845 in Healthy Volunteers. To evaluate the pharmacodynamics of PF-03882845 in Healthy Volunteers.</brief_summary>
	<brief_title>A Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-03882845 In Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs). Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Evidence or history of clinically significant disease. Past medical history of epididymitis, orchitis, sexually transmitted diseases (chlamydia, gonorrhea, etc.) or urinary tract infection. History of prostatitis or prostate surgery. Urinary catheterization or instrumentation within 12 months of screening. Inguinal or scrotal hernia. Current or history of congenital genital abnormalities. Baseline scrotal ultrasound scan showing unilateral or bilateral scrotal blood flow abnormalities or anatomic abnormalities (hydrocele, cysts, other), with the exception of small epididymal cysts and spermatoceles. Any condition possibly affecting drug absorption (eg, gastrectomy). Blood donation of approximately 1 pint (500 mL) within 56 days prior to dosing. History of sensitivity to spironolactone, eplerenone, or related compounds. Serum potassium &gt;5.5 mEq/L at screening or Day 0.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>